BSE · 539378
Soni Medicare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹31 Cr with net profit ₹-0 Cr — a -0.6% net margin, versus -5.9% the period before.
Shareholding
As of 2026-06-30
- Promoter69.79%
- Public30.21%
1,237 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.6× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Healthcare · ranked #50 of 79 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,29,234 Cr | 244.11 | 13.63 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,09,470 Cr | 73.81 | 10.19 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,634 Cr | 269.56 | 7.24 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,513 Cr | 50.7 | 9.37 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,038 Cr | 298.29 | 9.19 | 8.48% | 8.36% |
| Global Health Limited | ₹38,082 Cr | 264.25 | 9.61 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,895 Cr | 136.55 | 9.04 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,496 Cr | 239.03 | 12.55 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹16,888 Cr | 51.6 | 5.44 | 10.37% | 17.18% |
| Rainbow Childrens Medicare Ltd. | ₹15,420 Cr | 62.33 | 9.24 | 16.89% | 16.34% |
| Soni Medicare Limited(this company) | ₹24 Cr | — | — | 219.47% | -10.97% |
AI analysis
AI-generated · google/gemini-2.5-flashSoni Medicare Limited has a market capitalization of Rs 22 Cr. The company reported revenue of Rs 31.18 Cr and a negative profit margin of -10.97%. Its debt-to-equity ratio stands at 7, and the book value per share is -2.9. The promoter holding is 69.7883%.
Positives
- +Revenue increased to Rs 31.1844059 Cr in Mar 2025 from Rs 16.0656939 Cr in Mar 2021.
- +Return on Equity (ROE) is 219.47%, indicating potentially high returns on shareholders' capital, despite negative book value.
Negatives
- −The company has a negative book value per share of -2.9.
- −The profit margin is negative at -10.97%.
- −Net profit has been consistently negative in the last five annual periods.
- −The company has a high debt-to-equity ratio of 7.
- −The company is under 'GSM · GSM 1' surveillance.
- −Return on Capital Employed (ROCE) is negative at -11.6366%.
Financial performance
The company's revenue increased to Rs 31.18 Cr in Mar 2025. Over the last five financial years, revenue has generally grown, from Rs 16.0656939 Cr in Mar 2021 to Rs 31.1844059 Cr in Mar 2025. Net profit has remained negative, with a loss of Rs -0.1863768 Cr in Mar 2025, an improvement from a loss of Rs -1.6819214 Cr in Mar 2024. Earnings per share (EPS) was -0.74 in Mar 2025.
Profitability & returns
Soni Medicare Limited has a negative profit margin of -10.97%. The company's RoCE (Return on Capital Employed) is negative at -11.6366%. RoE (Return on Equity) is 219.47%. EBITDA was positive at Rs 0.7638321 Cr in Mar 2025, after a negative EBITDA of -0.7729987 Cr in Mar 2024.
Balance sheet
The company has a debt-to-equity ratio of 7, indicating a high level of debt relative to equity. The book value per share is negative at -2.9, suggesting that liabilities exceed assets. No information on current assets or liabilities is available in the provided data.
Ownership & pledges
The public shareholding stands at 30.2117%. There is no promoter pledging reported. No shares are held by DIIs or FIIs. The number of shareholders is 1237 as of 2026-06-30.
Regulatory & surveillance
Soni Medicare Limited is under surveillance with a 'GSM · GSM 1' label, which includes 'GSM' measures. This indicates increased scrutiny from regulatory bodies due to certain parameters being met.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.